Combination Trials with New IO Agents: How Can we Define the Best Treatment with Current Data?

Combination Trials with New IO Agents: How Can we Define the Best Treatment with Current Data?

User Photo
kidneycancer

2 years
103 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Bernard Escudier, Gustave Roussy, Villejuif, France asks teh question "Combination Trials with New IO Agents: How Can we Define the Best Treatment with Current Data?" at the 13th European International Kidney Cancer Symposium 2018 in Prague.
Up Next Autoplay